A subset analysis of efficacy and safety outcomes from phase 3 clinical studies of ixekizumab for the treatment of patients with severe plaque psoriasis

References

• Raychaudhuri SP. Role of IL-17 in psoriasis and psoriatic arthritis. Clin Rev Allerg Immunol. 2013;44(2):183–193.
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541–551.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Van den Bosch F, Roberson SA, et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum. 2010;62(4):929–939.
   PubMed Web of Science ®Google Scholar
• Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366(13):1190–1199.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345–356.
   PubMed Web of Science ®Google Scholar
• Reich K, Pinter A, Leutz A, et al. A 24-week, randomized, open-label comparison of ixekizumab versus fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naïve to systemic therapy. Abstract Presented at: 26th European Academy of Dermatology and Venereology Congress, September 13–17, 2017; Geneva, Switzerland.
   Google Scholar
• Reich K, Pinter A, Lacour JP, on behalf of the IXORA-S Investigators, et al. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study. Br J Dermatol. 2017;177(4):1014–1023.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Papp K, Gottlieb A, on behalf of the IXORA-R Investigators, et al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. Br J Dermatol. 2019. DOI:https://doi.org/10.1111/bjd.18851
   Web of Science ®Google Scholar
• Reich K, Leonardi C, Lebwohl M, et al. Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3). J Dermatolog Treat. 2017;28(4):282–287.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Gooderham M, Iversen L, et al. Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3). J Am Acad Dermatol. 2017;77(5):855–862.
   PubMed Web of Science ®Google Scholar
• Leonardi C, Maari C, Philipp S, et al. Maintenance of skin clearance with ixekizumab treatment of psoriasis: three-year results from the UNCOVER-3 study. J Am Acad Dermatol. 2018;79(5):824–830.e2.
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Gordon KB, Gallo G, et al. Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study. J Eur Acad Dermatol Venereol. 2020;34(2):301–309.
   PubMed Web of Science ®Google Scholar
• Louden BA, Pearce DJ, Lang W, et al. A Simplified Psoriasis Area Severity Index (SPASI) for rating psoriasis severity in clinic patients. Dermatol Online J. 2004;10(2):7.
   PubMedGoogle Scholar
• Australian Government Department of Human Services. Psoriasis – severe chronic plaque psoriasis – adult patients [Internet] [cited 2019 May 1]. Available from: https://www.humanservicesgov.au/organisations/health-professionals/enablers/severe-chronic-plaque-psoriasis.
   Google Scholar
• Camisa C. Handbook of psoriasis. Malden (MA): Blackwell Publishing Ltd; 2004.
   Google Scholar
• Di Lernia V, Ricci C, Lallas A, et al. Clinical predictors of non-response to any tumor necrosis factor (TNF) blockers: a retrospective study. J Dermatolog Treat. 2014;25(1):73–74.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Feldman SR, Korman NJ, et al. Assessing the overall benefit of a medication: cumulative benefit of secukinumab over time in patients with moderate-to-severe plaque psoriasis. *J Dermatolog Treat. 2017;28(3):200–205.
   PubMed Web of Science ®Google Scholar
• Costanzo A, Papoutsaki M, Mazzotta A, et al. Consecutive use of different biological therapies in the treatment of psoriasis. Br J Dermatol. 2007;157(2):394–394.
   PubMed Web of Science ®Google Scholar
• Costa L, Perricone C, Chimenti MS, et al. Switching between biological treatments in psoriatic arthritis: a review of the evidence. Drugs R D. 2017;17(4):509–522.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Papp KA, Griffiths CEM, et al. Efficacy and safety of switching to ixekizumab in etanercept non-responders: a subanalysis from two phase III randomized clinical trials in moderate-to-severe plaque psoriasis (UNCOVER-2 and -3). Am J Clin Dermatol. 2017;18(2):273–280.
   PubMed Web of Science ®Google Scholar
• Nash P, Kirkham B, Okada M, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet. 2017;389(10086):2317–2327.
   PubMed Web of Science ®Google Scholar
• McLaughlin M, Ostör A. Early treatment of psoriatic arthritis improves prognosis. Practitioner. 2014;258(1777):21–24.
   PubMedGoogle Scholar
• Kozub P, Simaljakova M. Systemic therapy of psoriasis: methotrexate. Bratisl Lek Listy. 2011;112(7):390–394.
   PubMed Web of Science ®Google Scholar
• Pearce DJ, Higgins KB, Stealey KH, et al. Adverse events from systemic therapies for psoriasis are common in clinical practice. J Dermatolog Treat. 2006;17(5):288–293.
   PubMed Web of Science ®Google Scholar